Stoquart Gaëtan G, Detrembleur Christine, Palumbo Sara, Deltombe Thierry, Lejeune Thierry M
Rehabilitation and Physical Medicine Unit, Université Catholique de Louvain, Brussels, Belgium.
Arch Phys Med Rehabil. 2008 Jan;89(1):56-61. doi: 10.1016/j.apmr.2007.08.131.
To study the effect of botulinum toxin type A (BTX-A) injection in the rectus femoris on the decreased knee flexion during the swing phase of gait (stiff-knee gait) in people with stroke.
Intervention study (before-after trial) with an observational design.
Outpatient rehabilitation clinic and gait laboratory.
Nineteen chronic hemiparetic adults presenting with stiff-knee gait.
Injection of 200 U of BTX-A (Botox) into the rectus femoris.
Before and 2 months after BTX-A rectus femoris injection: Stroke Impairment Assessment Set (SIAS), Duncan-Ely test, and an instrumented gait analysis.
Median SIAS score improved from 53 (range, 36-65) to 57 (range, 42-70) (signed-rank test, P=.005) and the Duncan-Ely score from 3 (range, 1-3) to 1 (range, 0-3) (P<.001). In gait analysis, mean (+/- standard deviation) maximum knee flexion improved from 26 degrees +/-13 degrees to 31 degrees +/-14 degrees during the swing phase (paired t test, P<.001), knee flexion speed at toe-off improved from 82 degrees +/-63 degrees to 112 degrees +/-75 degrees/s (P=.009), and knee negative joint power (eccentric muscular contraction) improved from -.27+/-.23 to -.37+/-.26 W/kg (P<.001). The 4 patients who almost did not flex the knee (<10 degrees) before the BTX-A rectus femoris injection did not improve after the injection. The other 14 patients who flexed the knee more than 10 degrees before the BTX-A rectus femoris injection decreased the walking energy cost from 5.4+/-1.6 to 4.6+/-1.3 J x kg(-1) x m(-1) (P=.006).
BTX-A rectus femoris injection may be beneficial in patients with a stiff-knee gait after stroke, particularly in patients with some knee flexion (>10 degrees).
研究A型肉毒毒素(BTX-A)注射到股直肌对中风患者步态摆动期膝关节屈曲减少(僵膝步态)的影响。
采用观察性设计的干预研究(前后试验)。
门诊康复诊所和步态实验室。
19名表现为僵膝步态的慢性偏瘫成年人。
向股直肌注射200 U的BTX-A(保妥适)。
在BTX-A注射到股直肌之前和之后2个月:中风损伤评估量表(SIAS)、邓肯 - 伊利试验以及仪器化步态分析。
SIAS评分中位数从53(范围36 - 65)提高到57(范围42 - 70)(符号秩检验,P = 0.005),邓肯 - 伊利评分从3(范围1 - 3)降至1(范围0 - 3)(P < 0.001)。在步态分析中,摆动期平均(±标准差)最大膝关节屈曲度从26°±13°提高到31°±14°(配对t检验,P < 0.001),足趾离地时膝关节屈曲速度从82°±63°提高到112°±75°/秒(P = 0.009),膝关节负关节功率(离心肌肉收缩)从 - 0.27±0.23提高到 - 0.37±0.26 W/kg(P < 0.001)。在BTX-A注射到股直肌之前几乎没有膝关节屈曲(<10°)的4名患者在注射后没有改善。在BTX-A注射到股直肌之前膝关节屈曲超过10°的其他14名患者将步行能量消耗从5.4±1.6降至4.6±1.3 J·kg⁻¹·m⁻¹(P = 0.006)。
BTX-A注射到股直肌可能对中风后僵膝步态患者有益,特别是对一些有膝关节屈曲(>10°)的患者。